NICE Failed to Recommend Boehringer Ingelheim and Lilly’s Jardiance (empagliflozin) for Heart Failure
- NICE was unable to recommend Jardiance for adults with symptomatic chronic HF with preserved or mildly reduced ejection fraction
- In other countries outside of the UK, empagliflozin has already been approved for reimbursement to treat patients with HF & mildly reduced or preserved ejection fraction
- Empagliflozin received a MHRA's marketing authorization as the first effective treatment for symptomatic chronic HF regardless of ejection fraction, based on the P-III trial (EMPEROR-Preserved) results & achieved primary composite EPs (CV death or hospitalization for HF) in adults with an ejection fraction of ≥40%. Both empagliflozin & PBO were added to background therapy in this trial
Ref: Pharmiweb | Image: NICE
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.